Despite their ability to create matter out of thin air, algae and cyanobacteria have long been neglected by the biotech industry. Recently, however, they have started to gain traction in new market niches.
In the center of Paris, just across from Marie Curies old laboratory, Pierre Crozet, Associate Professor at Sorbonne University, studies photosynthesis. His research focuses on making microalgae easier to engineer and thus more appealing to the industry. [Microalgae] are photosynthetic, and quite efficient at it, but require much less space or nutrients than land plants, he told me.
The idea that new technologies should serve sustainability has started taking root in society. Using photosynthetic microbes for biotech applications appears to be a no-brainer. Algae grow biomass literally out of thin air, only needing water, carbon dioxide, and inorganic nutrients. Many grow on seawater and in lands not suitable for agriculture.
Today, we are managing quite well in transforming algae. I would thus not consider it particularly difficult, says Crozet, pointing out that, nowadays, obtaining a new strain of algae using genetic engineering takes just weeks. So, technically, they should be able to effectively replace bacteria and yeast, which generally require more complex growth facilities as well as the input of a sugar source in order to be able to generate any product.
However, algae have historically not been considered a good alternative to yeast and bacteria because of their slower growth rate. In addition, the crash of many algae biofuel companies about a decade ago dealt a blow to the field that it still has trouble recovering from.
The early 2010s saw several startups forming to produce biofuels, mainly in the US. Many claimed to be close to offering algal biofuel at competitive market prices. Sapphire Energy, Solazyme, and Algenol, among others, received significant public and private investments and built up high expectations. But due to technological challenges and the drop in oil prices between 2015 and 2016, no product became commercially viable and these businesses either went bankrupt or had to radically change their focus.
The [challenge] of algae and cyanobacteria comes down to their slow growth and the cost of production, says Hugh Goold, Research Scientist at the NSW Department of Primary Industries, Australia. According to Goold, the resources required to keep photosynthesis going is very high, meaning they dont replicate as quickly as the bacteria and yeast commonly used in biotech applications.
Bacteria and yeast have been optimized for many years in biotech applications such as producing commodity chemicals as well as high-value compounds such as pharmaceuticals, meaning that photosynthetic organisms can no longer compete with these applications. Investors have to know that you are going to produce a product cheaper than other people can. It isnt worthwhile to produce something in algae instead of E. coli just because, said Goold.
Despite this challenge, algae and cyanobacteria have started to get interest from new market niches where they could offer key advantages over traditional bioproduction methods.
Microalgae capture sunlight using pigments of vibrant colors, such as chlorophylls, carotenoids, and phycocyanin. In particular, the algae spirulina and chlorella found their way to the market a long time ago as food supplements and food colorants. Algae are also an excellent source of protein, which opens up a lot of opportunities in the production of meat analogs and vegan food in general.
Unilever, a massive producer of food and other consumer goods, has seen the nutritional potential of microalgae, partnering with UK-based company Algenuity in July. Algae are a source of high-quality plant-based protein, said Manfred Aben, Vice President of Science & Technology at Unilever. These products will appeal to a variety of consumers; for vegans and vegetarians but also for flexitarians and meat-eaters looking to reduce their consumption of animal products.
Within the food and beverage sector, the opportunities for microalgae-based ingredients are strong and tangible, explained Andrew Spicer, CEO of Algenuity. We do anticipate applications for microalgae-based ingredients in markets other than food and beverages where similar drivers around sustainability, plant-based, and natural sources of ingredients are equally strong.
Last year, the Dutch food and biochemical company Corbion announced a similar partnership with Nestl, signaling that big players in the food industry are starting to increasingly recognize the potential value of algae products. Other companies gaining traction in the field are Algama in France seeking to provide meat alternatives, and AlgaEnergy in Spain producing food and feed as well as cosmetics and fertilizers from algae.
In 2011, Renana Krebs graduated from the Shenkar College of Engineering, Design, and Art in Tel Aviv with a degree in fashion. While working for fashion brands, she realized the huge impact the industry has on the environment. Clothes and textiles manufacturing accounts for 10% of global carbon emissions and 20% of wastewater. Looking for alternative solutions, Krebs teamed up with her father and founded Algalife, a German-Israeli company offering algae-based fibers and textiles.
Algalife stands for a better planet and a better fashion industry. We provide and enable the opportunity for everyone to make better choices, for a healthy, sustainable well-being, Krebs told me. The company collaborates with fashion brands that are willing to learn and adjust their practices to include the green fibers, and even pay more for sustainable solutions.
Renana Krebs considers algae as one of the most influential resources for sustainable development, and notes that she gets requests from companies outside the fashion industry.
Over in San Diego, California, the startup Algenesis has been using algae oil as a replacement for petroleum. The two first products launched by the startup, whose founders are all surfers, are a surfboard and flip flops made from an algal biopolymer that is biodegradable.
In addition to fashion, algae can also be used to produce sustainable alternatives to everyday petrochemical products. For example, the startup Living Ink, in the US, aims to provide an eco-friendly alternative to printing ink using cyanobacteria.
After some initial hiccups, algae seem to be finding their way into the market. The new generation of startups in this field focus more on business-to-business relationships but build their branding around customers demand for environmentally friendly products.
It seems clear that cyanobacteria and algae will not replace bacteria and yeast as fermentation organisms in traditional applications. However, they have unique characteristics and a potential waiting to be unlocked by more research and daring business ideas. I cannot see limitations to what can be done with algae, but our own imagination, noted Crozet.
Cover illustration by Elena Resko, pictures courtesy of AlgaEnergy and AlgaLife
Go here to see the original:
After Years of Neglect, Algae Biotechnology Makes a... - Labiotech.eu
- What's Going On With Liver Disease Focused Vir Biotechnology Stock Is Friday? - Yahoo Finance - November 16th, 2024
- Department of Biotechnology Launches Webinar Series on Biomanufacturing and Biofoundry Initiative - IBG NEWS - November 16th, 2024
- Multimodal scanning of genetic variants with base and prime editing - Nature.com - November 16th, 2024
- NEW INITIATIVE BY THE ITALIAN EMBASSY IN WASHINGTON ON BIOTECHNOLOGY WITH THE MILKEN INSTITUTE AND LEADING RESEARCHERS AND INDUSTRY EXPERTS -... - November 16th, 2024
- Vir Biotechnology Announces Positive End-of-Treatment Results for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B from the MARCH Study at... - November 16th, 2024
- Albany State offers new Master of Science in Integrated Biotechnology program - The Albany Herald - November 16th, 2024
- What's Going On With Liver Disease Focused Vir Biotechnology Stock Is Friday? - Benzinga - November 16th, 2024
- iNtRON Biotechnology (KOSDAQ:048530) Is In A Strong Position To Grow Its Business - Simply Wall St - November 16th, 2024
- PDS Biotechnology Highlights Clinical Progress and Q3 Results - TipRanks - November 16th, 2024
- We Think Puma Biotechnology's (NASDAQ:PBYI) Robust Earnings Are Conservative - Yahoo Finance - November 16th, 2024
- Puma Biotechnology's (NASDAQ:PBYI) Performance Is Even Better Than Its Earnings Suggest - Simply Wall St - November 16th, 2024
- APHIS Announces Final Notice on Additional Exemptions for the Movement of Organisms Modified or Produced Through Genetic Engineering - USDA APHIS - November 16th, 2024
- Adaptimmune nears second approval for TCR-T therapy - European Biotechnology News - November 16th, 2024
- Lundbeck reports 18% revenue growth in third quarter - The Pharma Letter - November 16th, 2024
- BioNTech to boost oncology offering with buy of Biotheus - The Pharma Letter - November 16th, 2024
- Puma Biotechnology Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance - November 16th, 2024
- WPI Receives Federal Funding to Address Anticipated Demand for Biology and Biotechnology Professionals and Educators - WPI News - November 3rd, 2024
- Jonathan Dinman to Direct the Institute for Bioscience and Biotechnology Research - College of Computer, Mathematical, and Natural Sciences - November 3rd, 2024
- PDS Biotechnology Co. (NASDAQ:PDSB) Given Average Recommendation of "Buy" by Analysts - MarketBeat - November 3rd, 2024
- COP16, DSI mechanism for benefit sharing from the use of digital sequence information approved - Renewable Matter - November 3rd, 2024
- Artificial Intelligence in Biotechnology Market to Hit USD 7.75 Billion by 2029 with 19.1% CAGR | MarketsandMarkets - PR Newswire - November 3rd, 2024
- Axonis Therapeutics raises $115 million in Series A financing - The Pharma Letter - November 3rd, 2024
- Regeneron third-quarter 2024 earnings top expectations - The Pharma Letter - November 3rd, 2024
- AbbVie inks up to $1.4 billion deal with EvolveImmune - The Pharma Letter - November 3rd, 2024
- CEO and Chairman of the Executive Board - European Biotechnology News - November 3rd, 2024
- The transformative potential of biotechnology and AI in healthcare - The Armchair Trader - November 3rd, 2024
- U.S. Biotechnology And Pharmaceutical Services Outsourcing Market Size to Reach USD 16.68 Billion By 2033 - BioSpace - October 6th, 2024
- Vir Biotechnology, Inc. (NASDAQ:VIR) is largely controlled by institutional shareholders who own 53% of the company - Yahoo Finance - October 6th, 2024
- Resolution Therapeutics scores 63.5 million in series B round - The Pharma Letter - October 6th, 2024
- Wiregrass Institute for Biotechnology welcomes local military veteran from Southeast Health as its first computational biologist - AOL - October 6th, 2024
- Generating and characterizing a comprehensive panel of CHO cells glycosylation mutants for advancing glycobiology and biotechnology research -... - October 6th, 2024
- Sapience Therapeutics Announces Participation at the 4th Annual Needham Private Biotech Company Virtual 1x1 Forum - PR Newswire - October 6th, 2024
- Spyre Therapeutics lures Abivax exec to be its CMO - The Pharma Letter - October 6th, 2024
- Convergence is AIxBio: AI and the Bioeconomy - OODA Loop - October 6th, 2024
- Congress targets Chinese influence in health tech. It could come with tradeoffs - ABC News - September 13th, 2024
- Researchers, media engage to educate farmers on biotechnology - University World News - September 13th, 2024
- Congress targets Chinese influence in health tech. It could come with tradeoffs - The Associated Press - September 13th, 2024
- Comer Delivers Remarks in Support of Bipartisan BIOSECURE Act - House Committee on Oversight and Reform | - September 13th, 2024
- Announcement of $2 Million for the University of Delaware to Advance Biotechnology - WGMD Radio - September 13th, 2024
- Thailand's Competitiveness Enhanced Through Advanced Biotechnology at Thailand LAB INTERNATIONAL 2024 - BSA bureau - September 13th, 2024
- Biotechnology company Amgen expands global reach with technology innovation center in Hyderabad, India - BioProcess Insider - September 13th, 2024
- Adam's Biotech Scorecard: Can iTeos and GSK solve TIGIT's troubles? - STAT - September 13th, 2024
- Cizzle Biotechnology Advancing Lung Cancer Detection from R&D to Application with Moffitt Cancer Centre (VIDEO) - DirectorsTalk Interviews - September 13th, 2024
- MAIA Biotechnology Announces Positive Survival Updates in Phase 2 Study of THIO in Non-Small Cell Lung Cancer - Business Wire - September 13th, 2024
- MAIA Biotechnology Advances with Clinical Trials and Partnerships - TipRanks - September 13th, 2024
- Viridian Therapeutics reports positive results for veligrotug - The Pharma Letter - September 13th, 2024
- Chinese biotech firms refute US bill, stressing they have no access to Americans personal data - Global Times - September 13th, 2024
- Vir Biotechnology Enhances Portfolio with Sanofi Deal and Executive Appointments - TipRanks - September 13th, 2024
- Tesla BioHealing and Cell Biotechnology Partner to Advance Stem Cell Therapies - Vancity Buzz - September 13th, 2024
- Time to leverage intellectual property to drive innovation in seed and biotechnology sectors: Experts - The Times of India - May 5th, 2024
- Where Does Capricor Therapeutics Inc (CAPR) Stock Fall in the Biotechnology Field After It Has Risen 24.73% This Week? - InvestorsObserver - March 10th, 2024
- Where Does SpringWorks Therapeutics Inc (SWTX) Stock Fall in the Biotechnology Field After It Has Gained 12.41% This Week? - InvestorsObserver - February 18th, 2024
- Should Biotechnology Stock Axsome Therapeutics Inc (AXSM) Be in Your Portfolio Wednesday? - InvestorsObserver - February 18th, 2024
- Where Does Candel Therapeutics Inc (CADL) Stock Fall in the Biotechnology Field After It Has Gained 22.38% This Week? - InvestorsObserver - February 18th, 2024
- What is Biotechnology? Types and Applications - Iberdrola - January 25th, 2024
- Where Does Immunitybio Inc (IBRX) Stock Fall in the Biotechnology Field After It Is Lower By -9.32% This Week? - InvestorsObserver - January 25th, 2024
- Can Sana Biotechnology Inc (SANA) Stock Rise to the Top of Healthcare Sector Monday? - InvestorsObserver - January 25th, 2024
- Should You Buy Sana Biotechnology Inc (SANA) Stock After it Has Fallen 15.41% in a Week? - InvestorsObserver - January 25th, 2024
- Where Does Tscan Therapeutics Inc (TCRX) Stock Fall in the Biotechnology Field After It Is Lower By -9.81% This Week? - InvestorsObserver - January 25th, 2024
- Should Biotechnology Stock Mink Therapeutics Inc (INKT) Be in Your Portfolio Monday? - InvestorsObserver - May 9th, 2023
- Where Does Ambrx Biopharma Inc - ADR (AMAM) Stock Fall in the Biotechnology Field After It Has Risen 22.18% This Week? - InvestorsObserver - May 9th, 2023
- Should Biotechnology Stock Dermata Therapeutics Inc (DRMA) Be in Your Portfolio Thursday? - InvestorsObserver - May 9th, 2023
- Should Biotechnology Stock Tempest Therapeutics Inc (TPST) Be in Your Portfolio Wednesday? - InvestorsObserver - May 9th, 2023
- Biotechnology - Applications of biotechnology | Britannica - May 1st, 2023
- Where Does BioLine RX Ltd - ADR (BLRX) Stock Fall in the Biotechnology Field After It Is Down -3.67% This Week? - InvestorsObserver - May 1st, 2023
- Where Does Apellis Pharmaceuticals Inc (APLS) Stock Fall in the Biotechnology Field After It Is Higher By 4.17% This Week? - InvestorsObserver - May 1st, 2023
- Where Does Aldeyra Therapeutics Inc (ALDX) Stock Fall in the Biotechnology Field After It Is Lower By -11.45% This Week? - InvestorsObserver - May 1st, 2023
- Is Rain Oncology Inc (RAIN) Stock at the Top of the Biotechnology Industry? - InvestorsObserver - April 7th, 2023
- Does Sana Biotechnology Inc (SANA) Have What it Takes to be in Your Portfolio Tuesday? - InvestorsObserver - April 7th, 2023
- Where Does Ambrx Biopharma Inc - ADR (AMAM) Stock Fall in the Biotechnology Field After It Is Lower By -15.43% This Week? - InvestorsObserver - April 7th, 2023
- Where Does Protagonist Therapeutics Inc (PTGX) Stock Fall in the Biotechnology Field After It Has Risen 3.62% This Week? - InvestorsObserver - April 7th, 2023
- What is Biotechnology? Definition, Types and Applications | TechTarget - March 21st, 2023
- Where Does Novavax Inc (NVAX) Stock Fall in the Biotechnology Field After It Is Lower By -12.99% This Week? - InvestorsObserver - March 21st, 2023
- Should Biotechnology Stock Outlook Therapeutics Inc (OTLK) Be in Your Portfolio Thursday? - InvestorsObserver - March 21st, 2023
- SANA BIOTECHNOLOGY, INC. : Results of Operations and Financial Condition, Financial Statements and Exhibits (form 8-K) - Marketscreener.com - March 21st, 2023
- Where Does Revance Therapeutics Inc (RVNC) Stock Fall in the Biotechnology Field After It Is Lower By -2.17% This Week? - InvestorsObserver - March 5th, 2023
- Is TG Therapeutics Inc common stock (TGTX) Stock at the Top of the Biotechnology Industry? - InvestorsObserver - March 5th, 2023
- Where Does GT Biopharma Inc (GTBP) Stock Fall in the Biotechnology Field After It Is Down -20.73% This Week? - InvestorsObserver - March 5th, 2023
- Where Does Dyne Therapeutics Inc (DYN) Stock Fall in the Biotechnology Field After It Is Lower By -2.35% This Week? - InvestorsObserver - March 5th, 2023
- Is CytomX Therapeutics Inc (CTMX) Stock at the Top of the Biotechnology Industry? - InvestorsObserver - November 17th, 2022